DNLI.US Denali Therapeutics Inc

Healthcare Biotechnology USA Stocks
18.74 USD
Close of Nov 13, 2026
15.34 27.30
Market cap
USD 3.00B
P/E
-
P/B
3.27x
ROE
-26.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DNLI.US undervalued?

Graham number

The Graham number of Denali Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Denali Therapeutics Inc fundamental analysis

No fundamental analysis for Denali Therapeutics Inc yet.

Denali Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enz…

Full company profile